AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
NEW YORK & SUZHOU, China--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeartâ€), a global clinical-stage biopharmaceutical company developing novel…